Determination of balance, fall risk, and kinesiophobia in individuals with Alzheimer’s Dementia DOI Creative Commons

Oğuzhan Doğancı,

Meral Sertel

Frontiers in Psychology, Journal Year: 2025, Volume and Issue: 16

Published: March 11, 2025

Objective This study aimed to determine balance, fall risk, and kinesiophobia in individuals with Alzheimer’s Dementia (AD). Methods The was completed 18 AD healthy AD-free control group early or moderate-stage diagnosed by a neurologist. Socio-demographic characteristics of the were assessed using an evaluation form, their balance evaluated Tinetti Balance Gait Assessment Test, Timed Up Go Single Leg Standing Test. Falls Risk Self-Assessment Scale (FRSAS) used assess risk falls. Kinesiophobia Tampa for (TKS). Additionally, participants underwent Mini-Mental State Examination (MMSE). Result mean age lower than that individuals, means 69 ± 3.66 years 65.4 4.10 years, respectively ( p = 0.012). 0.005), gait < 0.001), total (MMSE) 0,001) scores relative controls. FRSAS 0.001) higher TKS found be similar between 0.860). Conclusion It disease (AD) have poorer falls compared individuals. In light these results, assessments should included when developing rehabilitation protocols AD. Treatment designed this patient must incorporate balance-specific exercise training programs. individual environmental preventive measures implemented reduce Clinical trial registration Trial Number: NCT05201768.

Language: Английский

Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer’s disease DOI Creative Commons
Wei‐Ming Su, Xiaojing Gu, Meng Dou

et al.

Journal of Neurology Neurosurgery & Psychiatry, Journal Year: 2023, Volume and Issue: 94(11), P. 954 - 961

Published: June 22, 2023

Alzheimer's disease (AD) is the leading cause of dementia. Currently, there are no effective disease-modifying treatments for AD. Mendelian randomisation (MR) has been widely used to repurpose licensed drugs and discover novel therapeutic targets. Thus, we aimed identify targets AD analyse their pathophysiological mechanisms potential side effects.A two-sample MR integrating identified druggable genes was performed estimate causal effects blood brain expression quantitative trait loci (eQTLs) on A repeat study conducted using different eQTL data sources validate genes. Using markers with available genome-wide association studies data, evaluated relationship between established explore possible mechanisms. Finally, treatment were assessed a phenome-wide MR.Overall, 5883 unique aggregated; 33 in at least one dataset (brain or blood), 5 validated dataset. Among them, three prior (epoxide hydrolase 2 (EPHX2), SERPINB1 SIGLEC11) reached significant levels both tissues. EPHX2 may mediate pathogenesis by affecting entire hippocampal volume. Further analysis revealed targeting EPHX2, SIGLEC11.This provides genetic evidence supporting benefits treatment, which will be useful prioritising drug development.

Language: Английский

Citations

65
Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders DOI Creative Commons
Jessica R. Cohen,

Annette Mathew,

Kirk D. Dourvetakis

et al.

Cells, Journal Year: 2024, Volume and Issue: 13(6), P. 511 - 511

Published: March 14, 2024

Neuroinflammatory and neurodegenerative disorders including Alzheimer’s disease (AD), Parkinson’s (PD), traumatic brain injury (TBI) Amyotrophic lateral sclerosis (ALS) are chronic major health disorders. The exact mechanism of the neuroimmune dysfunctions these pathogeneses is currently not clearly understood. These show dysregulated inflammatory responses, activation neurons, glial cells, neurovascular unit damage associated with excessive release proinflammatory cytokines, chemokines, neurotoxic mediators, infiltration peripheral immune cells into brain, as well entry mediators through damaged endothelial blood–brain barrier tight junction proteins. Activation leads to many molecules that cause neuroinflammation neurodegeneration. Gulf War Illness (GWI) myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) also dysfunctions. Currently, there no effective disease-modifying therapeutic options available for diseases. Human induced pluripotent stem cell (iPSC)-derived astrocytes, microglia, pericytes used models drug discovery. This review highlights certain recent trends in neuroinflammatory responses iPSC-derived applications

Language: Английский

Citations

29
AI-Driven Innovations in Alzheimer's Disease: Integrating Early Diagnosis, Personalized Treatment, and Prognostic Modelling DOI
Mayur B. Kale, Nitu L. Wankhede,

Rupali S. Pawar

et al.

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: unknown, P. 102497 - 102497

Published: Sept. 1, 2024

Language: Английский

Citations

20
Salivary Biomarkers for Alzheimer’s Disease: A Systematic Review with Meta-Analysis DOI Open Access
Kacper Nijakowski,

Wojciech Owecki,

Jakub Jankowski

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(2), P. 1168 - 1168

Published: Jan. 18, 2024

Alzheimer’s Disease (AD) is the most common neurodegenerative disease which manifests with progressive cognitive impairment, leading to dementia. Considering noninvasive collection of saliva, we designed systematic review answer question “Are salivary biomarkers reliable for diagnosis Disease?” Following inclusion and exclusion criteria, 30 studies were included in this (according PRISMA statement guidelines). Potential include mainly proteins, metabolites even miRNAs. Based on meta-analysis, AD patients, levels beta-amyloid42 p-tau significantly increased, t-tau lactoferrin decreased at borderline statistical significance. However, according pooled AUC, showed a significant predictive value salivary-based diagnosis. In conclusion, potential markers such as beta-amyloid42, tau can be detected saliva could reliably support early disease.

Language: Английский

Citations

18
Pharmacological enhancement of slow-wave activity at an early disease stage improves cognition and reduces amyloid pathology in a mouse model of Alzheimer’s disease DOI Creative Commons
Sedef Kollarik,

Dorita Bimbiryte,

Aakriti Sethi

et al.

Frontiers in Aging Neuroscience, Journal Year: 2025, Volume and Issue: 16

Published: Jan. 3, 2025

Improving sleep in murine Alzheimer's disease (AD) is associated with reduced brain amyloidosis. However, the window of opportunity for successful sleep-targeted interventions, regarding reduction pathological hallmarks and related cognitive performance, remains poorly characterized. Here, we enhanced slow-wave activity (SWA) during via sodium oxybate (SO) oral administration 2 weeks at early (6 months old) or moderately late (11 stages Tg2576 mice evaluated resulting neuropathology behavioral performance. We observed that performance 6-month-old significantly improved upon SO treatment, whereas no change was 11-month-old mice. Histochemical assessment amyloid plaques demonstrated SO-treated had less plaque burden than placebo-treated ones, ELISA insoluble protein fractions from brains indicated lower Aβ-42/Aβ-40 ratio group vs. controls. Altogether, our results suggest SWA-dependent amyloidosis leads to alleviated impairment only if administered course, potentially highlighting key importance sleep-based interventions clinical cohorts.

Language: Английский

Citations

2
AdipoRon’s Impact on Alzheimer’s Disease—A Systematic Review and Meta-Analysis DOI Open Access
Sandra Maria Barbalho, Lucas Fornari Laurindo,

Bárbara de Oliveira Zanuso

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(2), P. 484 - 484

Published: Jan. 8, 2025

Alzheimer's disease (AD) remains a leading cause of cognitive decline and mortality worldwide, characterized by neurodegeneration, synaptic deficiencies, neuroinflammation. Despite advancements in early detection, diagnosis, treatment, AD presents substantial challenges due to its complex pathology, heterogeneity, the limited efficacy current therapies. Consequently, there is pressing need for novel therapeutic agents target multifaceted aspects enhance treatments, minimize adverse effects. AdipoRon, an adiponectin receptor agonist, has garnered interest potential neuroprotective effects, including reducing neuroinflammation, improving mitochondrial function, mitigating tau hyperphosphorylation. This review aimed evaluate effects AdipoRon-based replacement therapy against AD, using comprehensive approach grounded PICO framework-Population, Intervention, Comparison, Outcomes. A total six studies were reviewed, vitro vivo investigations examining AdipoRon's impact on various models. These involved different cell lines transgenic mouse models, assessing outcomes such as phosphorylation, relevant molecular pathways. By synthesizing data from these studies, our thoroughly explains mechanisms action, agent AD. analysis aims highlight state knowledge, identify gaps research, suggest directions future clinical applications.

Language: Английский

Citations

2
Advances in Drug Targeting, Drug Delivery, and Nanotechnology Applications: Therapeutic Significance in Cancer Treatment DOI Creative Commons
Fatih Çiftçi, Ali Can Özarslan, İmran Cagri Kantarci

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(1), P. 121 - 121

Published: Jan. 16, 2025

In the 21st century, thanks to advances in biotechnology and developing pharmaceutical technology, significant progress is being made effective drug design. Drug targeting aims ensure that acts only pathological area; it defined as ability accumulate selectively quantitatively target tissue or organ, regardless of chemical structure active substance method administration. With targeting, conventional, biotechnological gene-derived drugs body’s organs, tissues, cells can be transported specific regions. These systems serve carriers regulate timing release. Despite having many advantageous features, these have limitations thoroughly treating complex diseases such cancer. Therefore, combining with nanoparticle technologies imperative treat cancer at both local systemic levels effectively. The nanocarrier-based delivery involves encapsulating target-specific molecules into polymeric vesicular systems. Various (DDS) were investigated discussed this review article. first part passive systems, hydrogels, thermoplastics, microdevices transdermal-based second carrier nanobiotechnology (carbon nanotubes, nanoparticles, coated, pegylated, solid lipid nanoparticles smart nanogels). third part, advantages discussed, finally, market research commercial used nanotechnological approaches was included.

Language: Английский

Citations

2
The role of exosomes in diagnosis, pathophysiology, and management of Alzheimer's Disease DOI Creative Commons

Rajni Daksh,

Meby Susan Mathew,

Aan Mery Bosco

et al.

Biochemical and Biophysical Research Communications, Journal Year: 2025, Volume and Issue: 754, P. 151526 - 151526

Published: Feb. 22, 2025

Language: Английский

Citations

2
Nanomedicine in the Management of Alzheimer’s Disease: State-of-the-Art DOI Creative Commons
Shehla Nasar Mir Najib Ullah, Obaid Afzal, Abdulmalik Saleh Alfawaz Altamimi

et al.

Biomedicines, Journal Year: 2023, Volume and Issue: 11(6), P. 1752 - 1752

Published: June 18, 2023

Alzheimer’s disease (AD) is a deadly, progressive, and irreversible brain condition that impairs cognitive abilities. Globally, it affects 32.6 million individuals, if no viable therapies are available by 2050, figure might rise to 139 million. The current course of treatment enhances abilities temporarily relieves symptoms, but does not halt or slow the disease’s development. Additionally, treatments primarily offered in conventional oral dosage forms, lack specialization cause adverse effects, resulting poor patient compliance. A potential nanotechnology-based strategy can improve bioavailability specificity drug targeting brain. Furthermore, this review extensively summarizes applications nanomedicines for effective delivery drugs used management AD. In addition, clinical progress AD also discussed, challenges facing development addressed article.

Language: Английский

Citations

39
Amyloid Precursor Protein and Alzheimer’s Disease DOI Open Access

Kseniia S. Orobets,

Andrey L. Karamyshev

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(19), P. 14794 - 14794

Published: Sept. 30, 2023

Alzheimer's disease (AD) is one of the most common neurodegenerative disorders associated with age or inherited mutations. It characterized by severe dementia in late stages that affect memory, cognitive functions, and daily life overall. AD progression linked to accumulation cytotoxic amyloid beta (Aβ) hyperphosphorylated tau protein combined other pathological features such as synaptic loss, defective energy metabolism, imbalances protein, metal homeostasis. Several treatment options for are under investigation, including antibody-based therapy stem cell transplantation. Amyloid precursor (APP) a membrane considered play main role pathology. known APP physiological conditions follows non-amyloidogenic pathway; however, it can proceed an amyloidogenic scenario, which leads generation extracellular deleterious Aβ plaques. Not all steps biogenesis clear so far, these questions should be addressed future studies. complex chronic many factors contribute progression.

Language: Английский

Citations

34